Immunohistochemistry with Apoptotic-antiapoptotic Proteins (p53, P21, Bax, Bcl-2), C-kit, Telomerase, and Metallothionein As a Diagnostic Aid in Benign, Borderline, and Malignant Serous and Mucinous Ovarian Tumors

Overview

Journal Diagn Pathol

Publisher Biomed Central

Specialty Pathology

Date 2012 Sep 22

PMID 22995373

Citations 24

Authors

Hatice Ozer

Goncaimir Yenicesu

Sema Arici

Meral Cetin

Ersin Tuncer

Ali Cetin

Affiliations

Soon will be listed here.

Abstract

Background: In many tumors including ovarian cancer, cell proliferation and apoptosis are important in pathogenesis and there are many alterations in most of the genes related to the cell cycle. This study was designed to evaluate immunohistochemistry with apoptotic-antiapoptotic proteins (p53, p21, bax, and bcl-2), c-kit, telomerase, and metallothionein as a diagnostic aid in typing of benign, borderline, and malignant serous and mucinous ovarian tumors.

Methods: Total of 68 ovarian tumors, 25 benign [13 (19.1%) serous and 12 (17.6%) mucinous], 16 borderline [9 (13.2%) serous and 7(10.3%) mucinous], and 27 malignant ovarian tumors [24 (35.3%) serous and 3 (4.4%) mucinous tumors] were included in the study. Immunohistochemical expression of p53, p21, bax, bcl-2, telomerase, c-kit, and metallothionein were evaluated.

Results: When all 68 cases were evaluated as benign, borderline, and malignant ovarian tumors without considering histopathological subtypes, the p53, p21, bax and metallothionein showed significantly higher staining scores in the borderline and malignant ones (p < 0.05). After evaluation of all 68 cases, the serous tumors showed significantly higher staining scores of p53, p21, c-kit, and metallothionein compared to the mucinous ones (p < 0.05). For differentiation of benign and borderline and malignant tumors combined, p53 was not used because all benign tumors has no staining, and p21, bax, and metallothionein was determined the significant predictors for borderline and malignant tumors combined (p < 0.05). For differentiation of borderline and malignant tumors, only p53 was determined the significant predictor for malignant tumors (p < 0.05).

Conclusions: In conclusion, p53, p21, bax, c-kit, and metallothionein may be helpful for the typing of ovarian tumors as benign, borderline and malignant or serous and mucinous. p53, p21, bax, c-kit, and metallothionein may have different roles in the pathogenesis of ovarian tumor types. p53 and metallothionein may be helpful in the typing of borderline and malignant ovarian tumors. The immunohistochemical staining with bcl-2 and telomerase may not provide meaningful contribution for the typing of ovarian tumors.

Virtual Slide: The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/2013030833768498.

Citing Articles

Evaluation of Vincamine Loaded with Silver Nanoparticles as a New Potential Therapeutic Agent Against Ehrlich's Solid Carcinoma in Mice.

Dahran N, Othman M, Ghoniem M, Samak M, Elabbasy M, Obeidat S Cells. 2024; 13(21.

PMID: 39513869 PMC: 11545257. DOI: 10.3390/cells13211762.

Bisphosphonate's effect on the tongue in adult male albino rats and the possible protective role of rutin: light and scanning electron microscopic study.

El-Ghazouly D, Yassien R Anat Cell Biol. 2024; 57(1):129-142.

PMID: 38360060 PMC: 10968185. DOI: 10.5115/acb.23.230.

Evaluation of the in vitro and in vivo effect of liposomal doxorubicin along with oncolytic Newcastle disease virus on 4T1 cell line: Animal preclinical research.

Faranoush P, Jahandideh A, Nekouian R, Mortazavi P Vet Med Sci. 2023; 9(3):1426-1437.

PMID: 36920334 PMC: 10188073. DOI: 10.1002/vms3.1109.

Anti-Inflammatory and Antioxidant Effects of Carvacrol on -Methyl-'-Nitro--Nitrosoguanidine (MNNG) Induced Gastric Carcinogenesis in Wistar Rats.

Gunes-Bayir A, Guler E, Bilgin M, Ergun I, Kocyigit A, Dadak A Nutrients. 2022; 14(14).

PMID: 35889805 PMC: 9323991. DOI: 10.3390/nu14142848.

Association of recurrent mutations in BRCA1, BRCA2, RAD51C, PALB2, and CHEK2 with the risk of borderline ovarian tumor.

Ogrodniczak A, Menkiszak J, Gronwald J, Tomiczek-Szwiec J, Szwiec M, Cybulski C Hered Cancer Clin Pract. 2022; 20(1):11.

PMID: 35313928 PMC: 8935754. DOI: 10.1186/s13053-022-00218-0.

References

McGuire W . Maintenance therapy for ovarian cancer: of Helsinki and Hippocrates. J Clin Oncol. 2009; 27(28):4633-4. DOI: 10.1200/JCO.2009.23.6653. View

Parrott J, Kim G, Skinner M . Expression and action of kit ligand/stem cell factor in normal human and bovine ovarian surface epithelium and ovarian cancer. Biol Reprod. 2000; 62(6):1600-9. DOI: 10.1095/biolreprod62.6.1600. View

Hogg R, Scurry J, Kim S, Friedlander M, Hacker N . Microinvasion links ovarian serous borderline tumor and grade 1 invasive carcinoma. Gynecol Oncol. 2007; 106(1):44-51. DOI: 10.1016/j.ygyno.2007.01.054. View

Hartmann L, Podratz K, Keeney G, Kamel N, Edmonson J, Grill J . Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol. 1994; 12(1):64-9. DOI: 10.1200/JCO.1994.12.1.64. View

Barisik N, Bozkurt S, Gumus M, Kaygusuz I, Karadayi N, Bas E . Expression and prognostic significance of Cox-2 and p-53 in Hodgkin lymphomas: a retrospective study. Diagn Pathol. 2010; 5:19. PMC: 2853498. DOI: 10.1186/1746-1596-5-19. View

McCluggage W, Strand K, Abdulkadir A . Immunohistochemical localization of metallothionein in benign and malignant epithelial ovarian tumors. Int J Gynecol Cancer. 2002; 12(1):62-5. DOI: 10.1046/j.1525-1438.2002.01081.x. View

Mireskandari M, Shafaii A, Kayser G, Kayser K . Lack of CD117 and rare bcl-2 expression in stomach cancer by immunohistochemistry. An immunohistochemical study with review of the literature. Diagn Pathol. 2006; 1:7. PMC: 1475889. DOI: 10.1186/1746-1596-1-7. View

Tantbirojn P, Triratanachat S, Trivijitsilp P, Niruthisard S . Human telomerase reverse transcriptase (hTERT) expression in borderline ovarian tumors: an immunohistochemical study. J Med Assoc Thai. 2009; 92(3):308-14. View

Singer G, Stohr R, Cope L, Dehari R, Hartmann A, Cao D . Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol. 2005; 29(2):218-24. DOI: 10.1097/01.pas.0000146025.91953.8d. View

10.

Sun P, Wei L, Luo M, Liu G, Wang J, Mustea A . The telomerase activity and expression of hTERT gene can serve as indicators in the anti-cancer treatment of human ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 2006; 130(2):249-57. DOI: 10.1016/j.ejogrb.2006.01.028. View

11.

Abo-Elwafa H, Attia F, Sharaf A . The prognostic value of p53 mutation in pediatric marrow hypoplasia. Diagn Pathol. 2011; 6:58. PMC: 3142480. DOI: 10.1186/1746-1596-6-58. View

12.

Tonary A, Macdonald E, Faught W, Senterman M, Vanderhyden B . Lack of expression of c-KIT in ovarian cancers is associated with poor prognosis. Int J Cancer. 2000; 89(3):242-50. DOI: 10.1002/1097-0215(20000520)89:3<242::aid-ijc6>3.0.co;2-6. View

13.

Surowiak P, Materna V, Kaplenko I, Spaczynski M, Dietel M, Lage H . Augmented expression of metallothionein and glutathione S-transferase pi as unfavourable prognostic factors in cisplatin-treated ovarian cancer patients. Virchows Arch. 2005; 447(3):626-33. DOI: 10.1007/s00428-005-1228-0. View

14.

Omura G, Blessing J, Ehrlich C, Miller A, YORDAN E, Creasman W . A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study. Cancer. 1986; 57(9):1725-30. DOI: 10.1002/1097-0142(19860501)57:9<1725::aid-cncr2820570903>3.0.co;2-j. View

15.

Luo Y, Yi Y, Yao Z . Growth arrest in ovarian cancer cells by hTERT inhibition short-hairpin RNA targeting human telomerase reverse transcriptase induces immediate growth inhibition but not necessarily induces apoptosis in ovarian cancer cells. Cancer Invest. 2009; 27(10):960-70. DOI: 10.3109/07357900802491451. View

16.

Schuyer M, van der Burg M, Henzen-Logmans S, Fieret J, Klijn J, Look M . Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2. Br J Cancer. 2001; 85(9):1359-67. PMC: 2375252. DOI: 10.1054/bjoc.2001.2101. View

17.

Kim D, Lee M, Park T, Bae H . Expression and mutational analysis of c-kit in ovarian surface epithelial tumors. J Korean Med Sci. 2006; 21(1):81-5. PMC: 2733984. DOI: 10.3346/jkms.2006.21.1.81. View

18.

Havrilesky L, Darcy K, Hamdan H, Priore R, Leon J, Bell J . Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2003; 21(20):3814-25. DOI: 10.1200/JCO.2003.11.052. View

19.

Zagorianakou N, Stefanou D, Makrydimas G, Zagorianakou P, Briasoulis E, Karavasilis V . Clinicopathological study of metallothionein immunohistochemical expression, in benign, borderline and malignant ovarian epithelial tumors. Histol Histopathol. 2006; 21(4):341-7. DOI: 10.14670/HH-21.341. View

20.

Chan W, Cheung K, Schorge J, Huang L, Welch W, Bell D . Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers. Am J Pathol. 2000; 156(2):409-17. PMC: 1850061. DOI: 10.1016/S0002-9440(10)64744-X. View